NEWSROOM

ANEW MEDICAL, INC. Appoints New CFO

ANEW MEDICAL, INC. Appoints New CFO

New York, NY, August 19, 2024 - ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S.-based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related diseases, today announced the appointment of Jeffrey LeBlanc as the company’s Chief Financial Officer (CFO), replacing the interim CFO, Edward Cong Wang who was the former CFO of Redwoods Acquisition Corp into which ANEW merged. “Jeff LeBlanc is a highly experienced senior executive, and we...

read more
Sono-Tek to Present at August 20th Virtual Investor Summit Microcap Event

Sono-Tek to Present at August 20th Virtual Investor Summit Microcap Event

MILTON, NY, August 15, 2024 — Sono-Tek Corporation (Nasdaq: SOTK), a leading developer and manufacturer of ultrasonic coating systems, announced today that it will be presenting at the upcoming Virtual Investor Summit on August 20, 2024. Investors may request a one-on-one meeting with management by registering here: https://investorsummitgroup.com. Event: Q3 Investor SummitDate: August 20, 2024Presentation Time: 1:30 PM ETLocation: https://www.webcaster4.com/Webcast/Page/3062/51124 About...

read more
ANEW MEDICAL, INC. Appoints New CFO

ANEW MEDICAL, INC. Strengthens Intellectual Property Protection with U.S. Patent Issuance for Its Secreted RNA Splice Variant of the Human Klotho Gene Used for the Treatment of Neurodegenerative and Age-Related Diseases

Issuance of the Klotho gene-therapy patent will be instrumental in protecting ANEW’s IP for development and commercialization in the U.S. New York, NY, August 15, 2024 - ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA), a U.S.-based biotechnology company focused on developing cell and gene-based treatments for aging and age-related diseases; today announced the grant and issuance of U.S. Patent No. 12,036,268 (“the 268 patent”) covering the secreted RNA splice variant of the human...

read more
AmpliTech Group Reports Q2 Revenue of $2.5M with 1.05M Gross Profits and 42% Gross Margins

AmpliTech Group Reports Q2 Revenue of $2.5M with 1.05M Gross Profits and 42% Gross Margins

Hauppauge, NY, August 14, 2024 – AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, today announced its financial results for the second quarter ended June 30, 2024. The company plans to host an investor call within...

read more
American Shared Hospital Services Reports Strong Second Quarter 2024 Financial Results

American Shared Hospital Services Reports Strong Second Quarter 2024 Financial Results

Revenue increases 27% year over year Reports gain of $3.7 million from strategic acquisition of Rhode Island Radiation Therapy Cancer Centers Now treating patients at the new Puebla, Mexico center Conference Call on August 14th at 6:30 pm ET SAN FRANCISCO, CA, August 14, 2024 ‒ American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems and...

read more
American Shared Hospital Services Reports Strong Second Quarter 2024 Financial Results

American Shared Hospital Services Announces Second Quarter 2024 Earnings Conference Call

Call Scheduled for Today at 6:30 PM ET SAN FRANCISCO, August 14, 2024 - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a conference call to discuss its second quarter 2024 financial results today, August 14th at 6:30 pm ET / 3:30 pm PT. The second quarter 2024 financial results press release...

read more
Formation Minerals, Inc. Provides Fiscal Year End Corporate Update

Formation Minerals, Inc. Provides Fiscal Year End Corporate Update

Jacksboro, Texas, August 14, 2024 – Formation Minerals, Inc. (OTCQB: FOMI) (“Formation” or the “Company”), a growing oil and gas company with a focus on the acquisition and management of oil and gas minerals and royalties, today provided its fiscal year-end stockholder update. To our valued friends and stockholders, We hope that this letter finds you well and enjoying the summer. We at Formation continue to execute our strategy and are pleased to provide a corporate update in connection with...

read more
Metatron Announces QuantumBeam – A Revolution in AI-Controlled Energy Transmission

Metatron Announces QuantumBeam – A Revolution in AI-Controlled Energy Transmission

Dover, DE, August 13th, 2024 – Metatron Apps Inc (OTC: MRNJ) ($MRNJ), leading developer of over 1000 mobile apps proudly introduces QuantumBeam, a groundbreaking service that harnesses AI-designed and controlled cloud technology to deliver continuous energy transmission through quantum entanglement. This cutting-edge platform offers unparalleled benefits such as enhanced vitality, stress reduction, and EMF mitigation, backed by rigorous scientific studies demonstrating its effectiveness....

read more
Sono-Tek to Present at August 20th Virtual Investor Summit Microcap Event

Sono-Tek Announces Additional $2.95 Million Order from Specialty Clean Energy Customer

4 System Order Expected to be Shipped in Fiscal 2026 Company Experiencing Strong Demand from Clean Energy Sector MILTON, NY, August 13, 2024 — Sono-Tek Corporation (Nasdaq: SOTK), a leading developer and manufacturer of ultrasonic coating systems, is pleased to announce the receipt of an additional $2.95 million order from an existing clean energy customer. This new order, identical in value and scope to a recent record-breaking order from the same customer, reinforces Sono-Tek’s position as a...

read more
Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

Case Series represents second study showing VitaGraft Kidney as a measure of response to the benefit of therapy for one leading cause of allograft failure IRVINE, Calif., August 12, 2024 — Oncocyte Corp.  (Nasdaq: OCX), a molecular diagnostics technology company, announced the recent publication of a case series of two kidney transplant patients who were monitored for antibody-mediated rejection (AMR) using its proprietary VitaGraft™ Kidney diagnostic test. Patients were tested before, during...

read more

Contact Us

PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850